Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of Coronavirus vaccine

Trial Profile

Phase I/II study of Coronavirus vaccine

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2020

At a glance

  • Drugs Coronavirus vaccine-AdaptVac (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 May 2020 According to a Bavarian Nordic media release, company enters agreement with AdaptVac to advance COVID-19 vaccine program. The parties seek to enter into the final license agreement within the next two months.Current plan is to initiate a clinical study later this year.
    • 24 Apr 2020 According to an AdaptVac media release, the company announced signing of agreement with AGC Biologics for manufacture and scale-up of the COVID-19 (SARS-CoV-2) Coronavirus vaccine and this partnership has the potential to advance the initiation of this trial to the end of 2020.
    • 13 Mar 2020 New trial record

Trial Overview

Purpose

This phase I/II trial will evaluate Coronavirus vaccine.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations AdaptVac; AGC Biologics; Bavarian Nordic

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I/II
  • Location Unknown
  • Focus Adverse reactions; Therapeutic Use

Interventions

Drugs Route Formulation
Coronavirus vaccine-AdaptVacPrimary Drug
-
-

Coronavirus vaccine

Trial History

Event Date Event Type Comment
06 May 2020 Other trial event According to a Bavarian Nordic media release, company enters agreement with AdaptVac to advance COVID-19 vaccine program. The parties seek to enter into the final license agreement within the next two months.Current plan is to initiate a clinical study later this year. Updated 11 May 2020
24 Apr 2020 Other trial event According to an AdaptVac media release, the company announced signing of agreement with AGC Biologics for manufacture and scale-up of the COVID-19 (SARS-CoV-2) Coronavirus vaccine and this partnership has the potential to advance the initiation of this trial to the end of 2020. Updated 27 Apr 2020
13 Mar 2020 New trial record New trial record Updated 13 Mar 2020
09 Mar 2020 Other trial event According to an AdaptVac media release, PREVENT-nCoV consortium announces awarding of EU Horizon 2020 grant amounts of 2,7 MEUR to develop and test theCOVID-19 (SARS-CoV-2) Coronavirus vaccine in this trial. Updated 13 Mar 2020
09 Mar 2020 Other trial event According to an AdaptVac media release, the company plans to initiate this trial within 12 months. Updated 13 Mar 2020

References

  1. AdaptVac. PREVENT-nCoV consortium announces EU grant award for COVID-19 vaccine development programme. Media-Rel 2020;.

    Media Release
  2. AdaptVac. Manufacturing agreement with AGC Biologics accelerates COVID-19 vaccine program. Media-Rel 2020;.

    Media Release
  3. Bavarian Nordic. Bavarian Nordic Enters Agreement with AdaptVac to Advance COVID-19 Vaccine Program. Media-Rel 2020;.

    Media Release
Back to top